Nanjing Hicin Pharmaceutical Co., Ltd.'s (SZSE:300584) Stock Is Rallying But Financials Look Ambiguous: Will The Momentum Continue?
As of July 19th, Nanjing Hicin Pharmaceutical (300584.SZ) had a total of 14,162 shareholders.
Nanjing Hicin Pharmaceutical (300584.SZ) stated on the investor interaction platform that as of the close of July 10, the number of shareholders in the company was 13,705, and as of the close of July 19, the number of shareholders in the company was 14,162.
Shareholder Li Xiaquan reduced holdings of 782,700 shares of Nanjing Hicin Pharmaceutical (300584.SZ), reducing their holdings to less than 5%.
Nanjing Hicin Pharmaceutical (300584.SZ) issued an announcement that the company recently received a "Summary Equities Change Report" from shareholder Xiaquan Liu. As of the date of this announcement, Xiaquan Liu reduced the company's shares by 782,700 shares through centralized bidding, accounting for 0.65225% of the company's current total share capital. After this equity change, Xiaquan Liu's total shareholding in the company accounts for 4.99992% of the company's total share capital, and is no longer a shareholder holding more than 5% of the company.
Nanjing Hicin Pharmaceutical (300584.SZ): Received notification of approval for listing of chemical raw materials for propofol propofol Trovafloxacin.
On June 17th, Gelonhui reported that Nanjing Hicin Pharmaceutical (300584.SZ) received a notification of approval for the application to market chemical raw materials from the National Medical Products Administration. The chemical raw material name is Propofol fumarate Tenofovir alafenamide. Propofol fumarate Tenofovir alafenamide (TAF) is a prodrug of Tenofovir disoproxil fumarate (TDF), which is a potent antiviral drug. It has higher stability in plasma and can be more effectively delivered to liver cells, thus significantly reducing the risk of side effects by requiring much lower doses of TDF to achieve similar antiviral effects, with better bone and kidney safety.
Hicin Pharmaceutical Gets Registration Certificate for Tenofovir Alafenamide Fumarate Tablet
Nanjing Hicin Pharmaceutical (300584.SZ): Propofol substitute nucleoside antiviral tablets obtained drug registration approval.
On June 12th, Gelonhui reported that Nanjing Hicin Pharmaceutical (300584.SZ) recently received the "Drug Registration Certificate" issued by the State Drug Administration, with the drug name being propofol tenofovir tablets. The main ingredient of propofol tenofovir tablets is tenofovir alafenamide fumarate (TAF), which is a prodrug of tenofovir disoproxil fumarate (TDF), a potent antiviral drug. TAF has higher stability in plasma and can be more effectively delivered to liver cells, so the required dose for similar antiviral effect is far lower than TDF, significantly reducing the risk of side effects and having better bone safety.
Nanjing Hicin Pharmaceutical (300584.SZ) plans to distribute 0.5 yuan per 10 shares in 2023, ex-dividend on June 18th.
Nanjing Hicin Pharmaceutical (300584.SZ) announced its annual profit distribution plan for 2023: distribute to all shareholders ...
Haichen Pharmaceutical (300584.SZ): APIs for some products are actively exploring new processes, including using biofermentation to replace traditional chemical synthesis processes
Gelonghui May 9 丨 Some investors asked Haichen Pharmaceutical (300584.SZ) on the investor interactive platform, “Does the company have synthetic biotechnology-related technology reserves?” The company replied that the APIs for some of the company's products are actively exploring new processes, including using biological fermentation to replace traditional chemical synthesis processes to further reduce production costs and increase profit margins.
Haichen Pharmaceutical (300584.SZ) announced its 2023 annual results, with net profit of 363.15,600 yuan, an increase of 11.92% year-on-year
According to Zhitong Finance App, Haichen Pharmaceutical (300584.SZ) released its 2023 annual performance report. During the reporting period, the company achieved operating income of 518 million yuan, a year-on-year decrease of 1.64%; net profit attributable to shareholders of listed companies was 363.15,600 yuan, an increase of 11.92% over the previous year; net profit attributable to shareholders of listed companies after deducting non-recurring gains and losses was 369.653 million yuan, an increase of 17.51% over the previous year; the company plans to distribute a cash dividend of 0.5 yuan (tax included) for every 10 shares to all shareholders.
Liu Xiaoquan, the majority shareholder of Haichen Pharmaceutical (300584.SZ), plans to reduce holdings by no more than 1.082,700 shares
Haichen Pharmaceutical (300584.SZ) announced that Liu Xiaoquan, the company's shareholder holding more than 5% of the shares, plans to focus on bidding and big...
Liu Xiaoquan, the main shareholder of Haichen Pharmaceutical (300584.SZ), reduced its shares by 1%
Haichen Pharmaceutical (300584.SZ) announced that Liu Xiaoquan, the shareholder holding more than 5% of the company's shares, reduced the company's shares by 1...
Nanjing Hicin Pharmaceutical Co., Ltd. (SZSE:300584) Stock Rockets 26% As Investors Are Less Pessimistic Than Expected
Haichen Pharmaceutical (300584.SZ): Products suitable for mycoplasma pneumonia are mainly injectable azithromycin
Gelonghui March 6 丨 An investor asked Haichen Pharmaceutical (300584.SZ) on the investor interactive platform, “Does your company have drugs for mycoplasma pneumonia?” The company replied that the company's products for mycoplasma pneumonia are mainly injectable azithromycin.
Haichen Pharmaceutical (300584.SZ): The main products are injectable landilol hydrochloride, torasemide for injections, rivaroxaban tablets, and tigecycline for injections are all independently developed by the company
Gelonghui March 4 | Haichen Pharmaceutical (300584.SZ) said on the investor interactive platform that the company's main products, such as injectable landilol hydrochloride, injectable torasemide, rivaroxaban tablets, and tigecycline for injections are all independently developed by the company. Among them, injectable landiolol hydrochloride is the exclusive first imitation in China. At the end of 2023, it once again entered the national medical insurance catalogue with a simple contract renewal method; rivaroxaban tablets and injectable tigecycline were selected for centralized drug procurement nationwide. Pharmaceutical R&D innovation has the characteristics of difficulty, long cycle time, and high investment. In the future, the company will integrate clinical needs, its own R&D capabilities, and market conditions
Nanjing Hicin Pharmaceutical Co., Ltd.'s (SZSE:300584) 25% Share Price Plunge Could Signal Some Risk
Haichen Pharmaceutical (300584.SZ) obtained the high-tech enterprise certificate
Gelonghui, January 16, 丨 Haichen Pharmaceutical (300584.SZ) announced that the company recently received the “High-tech Enterprise Certificate” jointly issued by the Jiangsu Provincial Department of Science and Technology, the Jiangsu Provincial Department of Finance, and the Jiangsu Provincial Taxation Bureau of the State Administration of Taxation. The date of issue is November 6, 2023. The certificate number is GR202332007846, and the qualification is valid for three years.
Haichen Pharmaceutical (300584.SZ): Landilol hydrochloride for injection passed generic drug consistency evaluation
Gelonghui, December 1丨Haichen Pharmaceutical (300584.SZ) announced that recently, the company received the “Drug Supplement Application Approval Notice” for injectable landilol hydrochloride approved and issued by the State Drug Administration. The product passed the generic drug quality and efficacy consistency evaluation. Injectable landilol hydrochloride is a novel ultra-short-acting adrenaline beta blocker. This type of drug plays an important and irreplaceable role in the treatment of tachyarrhythmia due to its rapid action, rapid metabolism, and rapid beta-blocking effect after discontinuation of the drug. Landiolol hydrochloride for injection is Europe's “2020 ESC/EACTS heart
Haichen Pharmaceutical (300584.SZ): Net profit of 2,947,500 yuan in the third quarter increased by 24.84% year-on-year
Glonghui, October 26丨Haichen Pharmaceutical (300584.SZ) announced its report for the third quarter of 2023. Operating revenue for the reporting period was 116 million yuan, up 4.27% year on year; net profit attributable to shareholders of listed companies was 2.947,500 yuan, up 24.84% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 2,585.95 million yuan, up 10.98% year on year; basic earnings per share were 0.0246 yuan.
Insiders With Their Considerable Ownership Were the Key Benefactors as Nanjing Hicin Pharmaceutical Co., Ltd. (SZSE:300584) Touches CN¥3.3b Market Cap
Haichen Pharmaceutical (300584.SZ): Controlling shareholders, actual controllers, and directors and supervisors promise not to reduce their holdings of the company's shares
Glonghui, September 14, 丨 Haichen Pharmaceutical (300584.SZ) announced that it has recently received a “Letter of Commitment not to reduce company shares within the next six months” from the company's controlling shareholder, actual controller, Mr. Cao Yuping, Ms. Jiang Xiaoqun, and other directors and supervisors holding the company's shares (Supervisor Ms. Luo Yan, Deputy General Manager Mr. Liu Weicheng). The company's controlling shareholders, actual controllers, and other directors and supervisors holding the company's shares voluntarily promise not to reduce their holdings within six months from signing the letter of commitment (that is, September 14, 2023 to March 13, 2024) Shares , including that portion of the commitment period
No Data